Related Experiment Video
Updated: Dec 25, 2025
10:32
Implantation of Miniosmotic Pumps and Delivery of Tract Tracers to Study Brain Reorganization in Pathophysiological Conditions
Published on: January 18, 2016
14.6K
Novel Therapies in Hepatic Encephalopathy
Maryam Alimirah1, Omar Sadiq2, Stuart C Gordon3
1Department of Internal Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, CFP-1, Detroit, MI 48202, USA.
Clinics in Liver Disease
|April 5, 2020
Summary
Emerging therapies show promise for treating hepatic encephalopathy (HE), a serious complication of advanced liver disease. These new treatments aim to reduce cognitive impairment and improve outcomes for HE patients.
Area of Science:
- Hepatology
- Neuroscience
- Pharmacology
Background:
- Hepatic encephalopathy (HE) is a significant complication of advanced liver disease, leading to substantial morbidity and mortality.
- Current treatments like lactulose and rifaximin, while widely used, do not fully address the burden of HE.
- Cognitive impairment associated with HE significantly impacts patient quality of life and healthcare costs.
Purpose of the Study:
- To review and highlight promising emerging therapies for hepatic encephalopathy.
- To discuss the therapeutic targets of these novel agents.
- To provide an overview of advancements in managing HE-related cognitive dysfunction.
Main Methods:
- Literature review of recent studies and clinical trials.
- Analysis of emerging therapeutic agents and their mechanisms of action.
- Focus on agents targeting pathways involved in HE pathogenesis.
Main Results:
- Several novel therapeutic agents are under investigation for HE treatment.
- These agents target various pathways, including ammonia detoxification, inflammation, and neurotransmission.
- Early data suggests potential for improved efficacy in mitigating cognitive impairment.
Conclusions:
- Emerging therapies offer new hope for managing hepatic encephalopathy.
- Targeting specific pathways may lead to more effective treatments for HE.
- Further research is crucial to establish the safety and efficacy of these novel agents.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
691
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
691
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
451
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
451
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
01:26Psychosis: Goals of Pharmacotherapy
382
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
382
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
734
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
734
01:28Drug Therapy
198
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
198